CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry

MT Newswires Live09:52

CSL's (ASX:CSL) Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.

The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.

The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.

CSL shares gained 1% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654022877?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654022877","market":"hk","top_or_hot":-1,"title":"CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry","media":"MT Newswires Live","content":"<html><body><p> CSL's (ASX:CSL) Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.</p><p>The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.</p><p>The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.</p><p>CSL shares gained 1% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-28 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL's (ASX:CSL) Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.</p><p>The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.</p><p>The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.</p><p>CSL shares gained 1% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGXZ23171101.USD","symbol_name":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654022877","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654022877","pubTimestamp":1785203526,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL's  Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.CSL shares gained 1% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK7067":"生物科技","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7511":"ESG概念","BK7508":"医药生物股","BK7501":"新冠治疗股","CSL.AU":"CSL LIMITED","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4086":"建筑产品","CSL":"卡莱尔伙伴","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD"},"translate_title":"CSL 表示 Topline 3b 期结果支持寻求扩大 Andembry 儿科适应症的计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1.5,"CSL":1.5},"content_text":"CSL's (ASX:CSL) Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.CSL shares gained 1% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654022877","isCrawlerRequest":true}